China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025)
China SXT Pharmaceuticals (SXTC) recorded quarterly Current Deferred Revenue of $5240.0 in Q3 2025, down 91.06% quarter-over-quarter from $58627.0 in Q1 2025, and up 295.81% on a YoY basis from $1323.9 in Q3 2024.
China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025) Analysis & Trends
China SXT Pharmaceuticals' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $5240.0 for Q3 2025.
- In Q3 2025, Current Deferred Revenue rose 295.81% year-over-year to $5240.0; the TTM figure through Sep 2025 stood at $5240.0 (up 295.81% YoY), while the FY2025 annual figure was $58627.0, down 68.76% from the prior year.
- Current Deferred Revenue was $5240.0 for Q3 2025 at China SXT Pharmaceuticals, down from $58627.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $257449.0 in Q1 2021 to a low of -$2676.0 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $106813.5 across 5 years, with a median of $71233.5 in 2022.
- The sharpest annual moves came in 2021 and 2024: Current Deferred Revenue surged 341.3% in 2021, then slumped 107.61% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $218644.0 in 2021, then tumbled by 70.23% to $65101.0 in 2022, then tumbled by 45.95% to $35185.0 in 2023, then sank by 107.61% to -$2676.0 in 2024, then soared by 295.81% to $5240.0 in 2025.
- The last three Current Deferred Revenue figures came in at $5240.0 (Q3 2025), $58627.0 (Q1 2025), and -$2676.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | China SXT Pharmaceuticals | 187.96 Mn | 166.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5,240.00 |
| Mar 31, 2025 | 58,627.00 |
| Sep 30, 2024 | -2,676.00 |
| Mar 31, 2024 | 187,665.00 |
| Sep 30, 2023 | 35,185.00 |
| Mar 31, 2023 | 165,534.00 |
| Sep 30, 2022 | 65,101.00 |
| Mar 31, 2022 | 77,366.00 |
| Sep 30, 2021 | 218,644.00 |
| Mar 31, 2021 | 257,449.00 |
| Sep 30, 2020 | -90,609.00 |
| Mar 31, 2020 | 298,042.00 |
| Sep 30, 2019 | 120,575.00 |
| Mar 31, 2019 | 57,553.00 |
| Sep 30, 2018 | 117,992.00 |
| Mar 31, 2018 | 292,947.00 |